A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability
about
Chemokines and chemokine receptors: update on utility and challenges for the clinician.Structure-Based Identification of Novel Ligands Targeting Multiple Sites within a Chemokine-G-Protein-Coupled-Receptor InterfaceStructure-function analysis of CCL28 in the development of post-viral asthma.The role of chemoattractant receptors in shaping the tumor microenvironment.Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular α₁-adrenergic receptor function.Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine.Total body irradiation is permissive for mesenchymal stem cell-mediated new bone formation following local transplantation.Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies.Bacterial expression of the phosphodiester-binding site of the cation-independent mannose 6-phosphate receptor for crystallographic and NMR studiesPancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic SignalingPAX3 and FOXD3 Promote CXCR4 Expression in MelanomaMesenchymal stem cell expression of stromal cell-derived factor-1β augments bone formation in a model of local regenerative therapy.Caloric restriction and the adipokine leptin alter the SDF-1 signaling axis in bone marrow and in bone marrow derived mesenchymal stem cells.Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminusThe dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerizationSulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery.Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma.Enriching Traditional Protein-protein Interaction Networks with Alternative Conformations of Proteins.Exploiting agonist biased signaling of chemokines to target cancer.Interference with the CXCL12/CXCR4 axis as potential antitumor strategy: superiority of a sulfated galactofucan from the brown alga Saccharina latissima and fucoidan over heparins.Incorporation of heparin-binding proteins into preformed dextran sulfate-chitosan nanoparticles.Production of Recombinant Chemokines and Validation of Refolding.Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation.SDF-1α in glycan nanoparticles exhibits full activity and reduces pulmonary hypertension in rats.Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model.Chemokines from a Structural Perspective.Different contribution of chemokine N-terminal features attest a different ligand binding mode and a bias towards activation of the atypical chemokine receptor ACKR3/CXCR7 compared to CXCR4 and CXCR3.Identification and functional characterization of arginine vasopressin receptor 1A : atypical chemokine receptor 3 heteromers in vascular smooth muscle.Removal of a consensus proline is not sufficient to allow tetratricopeptide repeat oligomerization.Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities.Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers
P2860
Q27687402-3D2EAAF2-A583-44A4-BB4E-F9FA3C0D22C2Q27704531-A7EC6C0C-238A-4B07-A0CF-AC68A0F98E58Q30370396-4BEE84EB-208B-456D-9406-2C0DE70856CEQ33993124-645CB938-4C1C-4427-8A97-8E6C67C84295Q34416235-FB49C861-A69B-4020-BDBD-842F5C3288CDQ34631525-A1E40046-6431-4B91-A6C5-2ADFBC9E135DQ34652682-D8D227FC-86C1-41E8-8207-3501474E1930Q35213463-1E26714E-F5F3-4E88-8E69-3B74D334C238Q35528569-29F68C56-3432-4843-ADA0-B16AC448CFCCQ35562788-B250DEE7-1A63-4544-AE55-C12396888EDDQ36028025-536EBBC0-D8EF-4BFC-B0AD-F7723840A58CQ36065213-A6873F77-2CC8-4BA7-9E66-55A733AF63E6Q36445537-C2A54284-7441-45EE-95AA-BCCA566D153BQ36445542-9E62D246-21C9-4FC2-9EB4-210D585FD8A9Q36508793-E62028D9-A67D-4343-963D-3850730672DAQ36530735-2E95A5B6-E98C-4B07-8F9D-321EF3D148F9Q37198858-9A0C142C-0FD7-429D-95F0-E17967E80982Q38549236-79B6D88F-17C3-4065-9681-5F4F7AA8FC74Q38642227-5910B5B8-8D48-4FA1-A80D-661030C0B9B1Q38819497-31753F7B-B39A-4E65-8344-5EA42143BF32Q38886686-9B19261F-71F7-40B8-958A-8DEC8FCAE924Q39128225-2F62DA0B-FF31-448F-88B3-D40348BAE484Q39614761-62957C8F-5D41-4D56-9ED3-C7A6044793BAQ42380472-70111069-3514-41BD-8A60-AB91A68D357DQ42878149-330B9574-52F0-4913-A6D5-67CDAA44A2EFQ45930874-7CA30959-E8FF-47A3-9D9E-54CDBBCAC443Q47154563-68857705-8590-43D3-BEC9-D771F3CC284BQ47260364-66408843-82FE-44E1-AAF5-36FB365CCEBCQ48042730-FB3A62E3-4F80-42AB-8C1A-4827935F64B7Q48126999-8D9E38E3-169A-4017-89E9-7616F7226821Q53369837-9B38DCCD-1419-4E75-81F8-2F4A479DA012Q58694964-3F44A603-7806-43B1-8F91-4E9CD371C01D
P2860
A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A locked, dimeric CXCL12 varia ...... ue to enhanced serum stability
@ast
A locked, dimeric CXCL12 varia ...... ue to enhanced serum stability
@en
type
label
A locked, dimeric CXCL12 varia ...... ue to enhanced serum stability
@ast
A locked, dimeric CXCL12 varia ...... ue to enhanced serum stability
@en
prefLabel
A locked, dimeric CXCL12 varia ...... ue to enhanced serum stability
@ast
A locked, dimeric CXCL12 varia ...... ue to enhanced serum stability
@en
P2093
P2860
P1476
A locked, dimeric CXCL12 varia ...... ue to enhanced serum stability
@en
P2093
Brian F Volkman
Joshua J Ziarek
Sam T Hwang
Tomonori Takekoshi
P2860
P304
P356
10.1158/1535-7163.MCT-12-0494
P577
2012-08-06T00:00:00Z